Company intelligence / Profile preview

Sichuan Aobang Gude Pharmaceutical

Chengdu, Sichuan, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Sichuan Aobang Gude Pharmaceutical is a commercial-stage pharmaceutical company focused on the development and manufacturing of high-difficulty APIs and therapeutic drugs. Key recent developments include the Phase 3 clinical trial of brivaracetam for partial epilepsy in China and the commercialization of fondaparinux sodium, which is listed in the FDA's DMF registry. The company also recently received approvals for several generic cardiovascular and CNS medications.

Therapeutic areas: HematologyCardiovascularNeurologyPulmonologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Sichuan UniversityChina Pharmaceutical UniversityShenyang Pharmaceutical University

Beyond the preview

Go deeper on Sichuan Aobang Gude Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Aobang Gude Pharmaceutical.

Explore the full profile